Textiles & Apparel Global On demand · 24-48h

Global Shoes for Arthritis Market Strategic Research Report

Global Shoes for Arthritis Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Shoes for Arthritis Market
$1.71B2025
4.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Rocker Bottom Shoes, Pressure Dispersion Shoes, Stabilization and Support Shoes, Cushioning and Shock Absorption Shoes, Custom Orthopedic Shoes

By Application: Specialty Store, Supermarket, Online Sales, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Orthofeet, Dr. Comfort, Aetrex, Drew Shoe, Apex Foot Health Industries, Propét, KURU Footwear, Vionic, SAS, Clarks, Skechers, Easy Spirit, New Balance, Klogs, Mephisto, ECCO, Birkenstock, Finn Comfort, OOFOS, Kizik, Gravity Defyer, Revitalign, ProTalus, Alegria, Aravon, Lifestride, DARCO International, Podartis, Duna, Dr. Zen, Dr. Foot, Horng Shin Footwear

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 221 pages
Market size 2025
$1.71B
Billion USD
Forecast CAGR
4.5%
2025-2032
Forecast 2032
$2.3B
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Shoes for Arthritis market size is predicted to grow from US$ 1,711 million in 2025 to US$ 2,310 million in 2032; it is expected to grow at a CAGR of 4.5% from 2026 to 2032.

Shoes for arthritis are specialized footwear designed with extra cushioning, deep & wide toe boxes, arch support, and soft, flexible materials to reduce pain, pressure, and inflammation for people with osteoarthritis or rheumatoid arthritis, accommodating swollen joints and deformities like bunions or hammertoes for better comfort and stability. Key features include shock absorption, smooth rocker soles, and adjustable closures, helping distribute weight and ease movement.

Global production of shoes for arthritis is projected to reach 22 million pairs by 2025, with an average price of $79.50 per pair. Gross profit margins typically range from 45% to 70%.

The upstream supply chain of shoes for arthritis mainly includes upper fabrics and leather, cushioning and support midsole materials such as EVA and PU, rubber outsoles, insole foam, and orthotic accessories. The lightweight, softness, and durability of upstream materials directly affect wearing comfort and product positioning. The downstream is key to value realization, with core users being people with osteoarthritis, rheumatoid arthritis, and those recovering from surgery. Their needs are concentrated on functions such as pressure reduction, joint stability, and ease of on/off. Sales channels are developing in parallel through medical-related channels and consumer channels. Hospital rehabilitation departments, orthopedic clinics, and orthotic device institutions emphasize functionality and professional endorsement, often relying on doctor recommendations or using the shoes in conjunction with orthotic insoles. Pharmacies, health product chains, e-commerce platforms, and brand stores cover a wider range of patients with mild to moderate arthritis and the elderly, emphasizing everyday comfort and appearance. End users have moderate price sensitivity, prioritizing pain relief, long-term wearing experience, and after-sales service, resulting in a high repurchase rate.

The industry is showing a trend of functional medical applications alongside everyday aesthetics, with customized insoles, adjustable structures, and intelligent foot assessments becoming increasingly common. Meanwhile, online direct sales and cross-border e-commerce are improving brand reach efficiency. Driving factors primarily include an aging population, rising arthritis prevalence, increased health management awareness, and growing demand for home rehabilitation. Obstacles include insufficient consumer awareness of professional footwear, limited medical insurance coverage leading to higher out-of-pocket expenses, and competition from similar comfort footwear products.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Shoes for Arthritis market?

What factors are driving Shoes for Arthritis market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Shoes for Arthritis market opportunities vary by end market size?

How does Shoes for Arthritis break out by Type, by Application?

This report presents a comprehensive overview of the global Shoes for Arthritis market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Rocker Bottom Shoes
  • Pressure Dispersion Shoes
  • Stabilization and Support Shoes
  • Cushioning and Shock Absorption Shoes
  • Custom Orthopedic Shoes

Segment by Shoe Type

  • Sneakers
  • Ankle Boots
  • Sandals
  • Slippers
  • Others

Segment by Material

  • Elastic Knit/Flyknit
  • Soft Leather/Synthetic Leather
  • Seamless Lining
  • Breathable Mesh
  • Others

Segment by Application

  • Specialty Store
  • Supermarket
  • Online Sales
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Shoes for Arthritis market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Specialty Store, Supermarket, Online Sales evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Shoes for Arthritis Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.71B
2025
Forecast
$2.3B
2032
CAGR
4.5%
2025–2032
Regionen
5
global
Key companies
OrthofeetDr. ComfortAetrexDrew ShoeApex Foot Health IndustriesPropétKURU FootwearVionic
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Rocker Bottom ShoesPressure Dispersion ShoesStabilization and Support ShoesCushioning and Shock Absorption ShoesCustom Orthopedic Shoes
By Application
Specialty StoreSupermarketOnline SalesOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Rocker Bottom Shoes
  • 3.1.3 Pressure Dispersion Shoes
  • 3.1.4 Stabilization and Support Shoes
  • 3.1.5 Cushioning and Shock Absorption Shoes
  • 3.1.6 Custom Orthopedic Shoes
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Specialty Store
  • 4.1.3 Supermarket
  • 4.1.4 Online Sales
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Orthofeet
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Dr. Comfort
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Aetrex
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Drew Shoe
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Apex Foot Health Industries
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Propét
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 KURU Footwear
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Vionic
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 SAS
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Clarks
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Skechers
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Easy Spirit
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 New Balance
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Klogs
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Mephisto
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 ECCO
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Birkenstock
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Finn Comfort
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 OOFOS
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Kizik
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Gravity Defyer
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Revitalign
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 ProTalus
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Alegria
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Aravon
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Lifestride
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 DARCO International
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 Podartis
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 Duna
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 Dr. Zen
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
  • 8.31 Dr. Foot
  • 8.31.1 Company Overview
  • 8.31.2 Key Products & Segments
  • 8.31.3 Financial Performance (2023–2025)
  • 8.31.4 Business Strategy
  • 8.31.5 SWOT Analysis
  • 8.31.6 Strategic Implications (2026–2032)
  • 8.32 Horng Shin Footwear
  • 8.32.1 Company Overview
  • 8.32.2 Key Products & Segments
  • 8.32.3 Financial Performance (2023–2025)
  • 8.32.4 Business Strategy
  • 8.32.5 SWOT Analysis
  • 8.32.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Shoes for Arthritis market size?
The global Shoes for Arthritis market is estimated at US$ 1.71 billion in 2025 (base year) and is projected to reach US$ 2.31 billion by 2032.
What growth rate is expected for the Shoes for Arthritis market through 2032?
The market is expected to grow at a CAGR of 4.5% from 2026 to 2032, expanding from US$ 1.71 billion in 2025 to US$ 2.31 billion in 2032, roughly 1.4 times its base-year value.
How is Shoes for Arthritis defined?
Shoes for arthritis are specialized footwear designed with extra cushioning, deep & wide toe boxes, arch support, and soft, flexible materials to reduce pain, pressure, and inflammation for people with osteoarthritis or rheumatoid arthritis, accommodating swollen joints and deformities like bunions or hammertoes for better comfort and stability. Key features include shock absorption, smooth rocker soles, and adjustable closures, helping distribute weight and ease movement.
What are the main segments of the Shoes for Arthritis market by type?
By type, the market is segmented into Rocker Bottom Shoes, Pressure Dispersion Shoes, Stabilization and Support Shoes, Cushioning and Shock Absorption Shoes and Custom Orthopedic Shoes.
Which applications drive demand in the Shoes for Arthritis market?
Key applications covered include Specialty Store, Supermarket, Online Sales and Other.
Who are the key players in the Shoes for Arthritis market?
Key players profiled include Orthofeet, Dr. Comfort, Aetrex, Drew Shoe, Apex Foot Health Industries, Propét, KURU Footwear and Vionic, among 32 companies covered in total.
Which regions and countries are covered for Shoes for Arthritis?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Shoes for Arthritis market?
Driving factors primarily include an aging population, rising arthritis prevalence, increased health management awareness, and growing demand for home rehabilitation.
Who should buy the Shoes for Arthritis market report?
The report is intended for manufacturers and solution providers, distributors and end users in Specialty Store, Supermarket and Online Sales, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Shoes for Arthritis market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.